Interim Report 3 2024/25
NOVEMBER 2024 – JANUARY 2025
| Net sales | 6 481 (4 873) KSEK |
| Operating result before depreciation (EBITDA) | -987 (-3 179) KSEK |
| Net result | -2 681 (-5 152) KSEK |
| Earnings per share | -0.08 (-0.21) SEK |
| Gross margin | 76 (72) % |
MAY 2024 – JANUARY 2025
| Net sales | 10 796 (8 824) KSEK |
| Operating result before depreciation (EBITDA) | -8 510 (-9 568) KSEK |
| Net result | -12 280 (-14 826) KSEK |
| Earnings per share | -0.34 (-0.58) SEK |
| Gross margin | 71 (73) % |
IN SHORT
- Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year.
- Gross margin continues to be strong, even slightly above planned levels (+4pp).
- Overall costs remain stable and as per plan; higher admin costs (capital raise connected) vs. lower R&D expenses.
- The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline & company potential.
CEO Commentary
Having recently taken on the role of acting CEO at PHI, my primary focus is execution—translating the Company’s potential into tangible results. We have a strong foundation built on deep technical expertise and a clear commitment to advancing regenerative medicine. Now, it’s time to maximize that potential.
Our path forward is clear: be the best at what we know best. This means focusing on cutting-edge imaging technology that empowers cell research and therapy, supported by a strong distributor network and strategic partnerships. Our recent financial performance demonstrates that we are moving in the right direction, with growing sales and a strong gross margin. However, we must accelerate further, ensuring our innovations reach the market at scale.
With a committed team, solid industry relationships, and a clear mission, we are ready to take PHI to the next level. The focus now is on execution and delivering on our promises—because the opportunity ahead is too great not to seize.
Ivan Jurkovic, CEO